Preston Schneider
Cardiovascular Disease · Bozeman, MTNPI 1922240621
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $84 of the $96 with a category attached, or 87.0%. 5 manufacturers reported payments, led by Philips North America LLC at 37.9% of the total. 2023 is the largest year on record at $51, 4.1 times the $12 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in MT, where the typical reported total is $1,321.
Across 6 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$36
- E.r. Squibb & Sons, L.L.C.$21
- Boston Scientific$15
- Regeneron Healthcare Solutions, Inc.$12
- Pfizer$12
Across 58 payments — averaging $268.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$12K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
What the payments were for
- Food & beverage$8487%
- Education$1213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Boston Scientific | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
How this compares
$96 in reported general payments places this provider in the 10th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $414,716 |
| EntrestoSacubitril/Valsartan | 146 | $163,426 |
| XareltoRivaroxaban | 132 | $160,088 |
| Repatha SureclickEvolocumab | 117 | $136,968 |
| FarxigaDapagliflozin Propanediol | 122 | $116,773 |
| JardianceEmpagliflozin | 91 | $98,472 |
| Praluent PenAlirocumab | 63 | $48,794 |
| Repatha SyringeEvolocumab | 15 | $14,712 |
| Atorvastatin Calcium | 628 | $9,896 |
| Metoprolol Succinate | 488 | $9,520 |
| Rosuvastatin Calcium | 607 | $8,766 |
| Ezetimibe | 222 | $5,545 |
| Losartan Potassium | 245 | $2,396 |
| Valsartan | 60 | $1,944 |
| Carvedilol | 189 | $1,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $414,716378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Bozeman
- Dane SobekBozeman$8K
- Vincenzo PolsinelliBozeman$1K
- Ronald ChinBozeman$1K
- Sara KlingerBozeman$284
- Sean BellBozeman$181
- Blair ErbBozeman$81
- Alexander TaylorBozeman$67
- Benjamin PlankBillings$46K
- Alrich GrayGreat Falls$34K
- Robert MitchellKalispell$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.